We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

391 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 41

65% more call options, than puts

Call options by funds: $93.9M | Put options by funds: $56.8M

33% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 103

18% more capital invested

Capital invested by funds: $8.09B → $9.56B (+$1.48B)

18% more funds holding

Funds holding: 332 → 391 (+59)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

1.37% less ownership

Funds ownership: 98.02% → 96.65% (-1.4%)

Holders
391
Holders Change
+59
Holders Change %
+17.77%
% of All Funds
7.7%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
109
Increased
137
Reduced
103
Closed
41
Calls
$93.9M
Puts
$56.8M
Net Calls
+$37.1M
Net Calls Change
+$33.9M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$77M
2
BlackRock
BlackRock
New York
+$68.6M
3
State Street
State Street
Massachusetts
+$65.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$58.7M
5
Ameriprise
Ameriprise
Minnesota
+$34M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$138M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$118M
3
HM
HealthCor Management
New York
-$71.9M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$68.6M
5
O
OrbiMed
New York
-$66.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
LI
176
Leap Investments
Illinois
$2.1M +$2.04M +19,500 New
GT
177
Glenmede Trust
Pennsylvania
$2.07M +$112K +1,066 +6%
RPI
178
Railway Pension Investments
United Kingdom
$2.06M +$2.01M +19,200 New
KAS
179
Kemnay Advisory Services
New York
$1.95M +$1.9M +18,140 New
Zurich Cantonal Bank
180
Zurich Cantonal Bank
Switzerland
$1.92M +$1.27M +12,153 +212%
URS
181
Utah Retirement Systems
Utah
$1.85M – – –
BF
182
BOK Financial
Oklahoma
$1.84M -$66.6K -636 -4%
Aviva
183
Aviva
United Kingdom
$1.8M +$1.75M +16,728 New
Daiwa Securities Group
184
Daiwa Securities Group
Japan
$1.69M -$608K -5,807 -27%
MWM
185
Mission Wealth Management
California
$1.66M +$533K +5,088 +49%
Toronto Dominion Bank
186
Toronto Dominion Bank
Ontario, Canada
$1.64M +$1.59M +15,231 New
Verition Fund Management
187
Verition Fund Management
Connecticut
$1.64M +$1.28M +12,202 +405%
CM
188
Caption Management
Oklahoma
$1.63M +$1.59M +15,200 New
IHAM
189
Integral Health Asset Management
New York
$1.61M +$1.57M +15,000 New
WC
190
Woodstock Corp
Massachusetts
$1.6M – – –
Public Employees Retirement Association of Colorado
191
Public Employees Retirement Association of Colorado
Colorado
$1.59M – – –
HSBC Holdings
192
HSBC Holdings
United Kingdom
$1.58M -$423K -4,039 -22%
Mitsubishi UFJ Asset Management
193
Mitsubishi UFJ Asset Management
Japan
$1.57M +$1.5M +14,321 New
XK
194
Xact Kapitalforvaltning
Sweden
$1.57M – – –
GCP
195
GSA Capital Partners
United Kingdom
$1.57M +$988K +9,440 +184%
BCM
196
Bayesian Capital Management
New York
$1.52M +$1.49M +14,184 New
ACI
197
AMP Capital Investors
Australia
$1.5M +$1.47M +14,030 New
ACM
198
AlphaCrest Capital Management
New York
$1.41M -$41.7K -398 -3%
AC
199
Athanor Capital
New York
$1.4M +$199K +1,900 +17%
AC
200
Allstate Corporation
Illinois
$1.4M – – –
6 7
8
9 10

NBIX Hedge Fund Activity: Q4 2019 in Review

391 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2019, worth a combined $9.56B — up 18% from $8.09B a quarter earlier.

Buyers outnumbered sellers: 109 funds opened new NBIX positions and 41 closed out — a net gain of 68 holders — while 137 added to existing stakes and 103 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $77M. The largest seller was Fidelity Investments, cutting an estimated $138M.

  • 391 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2019, up from 332 in Q3 2019.
  • Funds reported $9.56B of Neurocrine Biosciences stock for Q4 2019, up 18% quarter-over-quarter.
  • 109 funds opened new Neurocrine Biosciences positions in Q4 2019 and 41 closed out, a net change of +68 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $77M added.
  • The largest Neurocrine Biosciences seller in Q4 2019 was Fidelity Investments, an estimated $138M sold.

Based on aggregated 13F filings for Q4 2019.